Accepted for Publication: April 19, 2022.
Published Online: June 15, 2022. doi:10.1001/jamadermatol.2022.2044
Corresponding Author: Arash Mostaghimi, MD, MPA, MPH, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115 (amostaghimi@bwh.harvard.edu).
Author Contributions: Drs Mostaghimi and Barbieri had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Barbieri and Mostaghimi contributed equally to the work.
Concept and design: Xia, Han, Faletsky, Baldwin, Dréno, Goh, Kircik, Mann, Webster, Thiboutot, Zaenglein, Barbieri, Mostaghimi.
Acquisition, analysis, or interpretation of data: Xia, Han, Baldwin, Beleznay, Bettoli, Goh, Stein Gold, Gollnick, Herane, Kang, Kircik, Nast, Oon, See, Tollefson, Webster, Zip, Tan, Tapper, Thiboutot, Zaenglein, Barbieri, Mostaghimi.
Drafting of the manuscript: Xia, Stein Gold, Oon, Zip, Barbieri, Mostaghimi.
Critical revision of the manuscript for important intellectual content: Xia, Han, Faletsky, Baldwin, Beleznay, Bettoli, Dréno, Goh, Stein Gold, Gollnick, Herane, Kang, Kircik, Mann, Nast, Oon, See, Tollefson, Webster, Tan, Tapper, Thiboutot, Zaenglein, Barbieri, Mostaghimi.
Statistical analysis: Goh, Barbieri, Mostaghimi.
Administrative, technical, or material support: Han, Faletsky, Baldwin, Beleznay, Kang, Mann, Nast, Oon, Webster, Thiboutot, Mostaghimi.
Supervision: Bettoli, Dréno, Goh, Stein Gold, Kircik, Mann, Webster, Barbieri, Mostaghimi.
Conflict of Interest Disclosures: Mr Xia reported receiving grants from the Boston University School of Medicine Medical Student Summer Research Program during the conduct of the study. Dr Baldwin reported receiving speaking fees from Sun Pharma outside the submitted work. Dr. Beleznay has acted as an advisor, consultant, investigator, and/or speaker for: AbbVie, Allergan, Bausch Health, CeraVe, Cipher, Galderma, Johnson & Johnson, La Roche Posay, LEO Pharma, L’Oréal, Procter & Gamble, Revance, Sanofi, SkinCeuticals, and Vichy. Dr. Bettoli has acted as consultant, advisory board member, research investigator and received honoraria from AbbVie, Baiersdorf, Bioderma, Biogena, Difa-Cooper, Galderma, GSK, ICF, LEO Pharma, L’Oréal, Meda, Menarini-Relife, Mylan, Novartis, Pharcos-Biodue, UCB Pharma, and received research support (funds to institution) from AbbVie. Dr Dréno reported receiving personal fees from Galderma during the conduct of the study. Dr. Goh is a medical advisory member of Cantabria Lab (Spain) and a member of the photoprotection panel at La Roche-Posay. Dr Stein Gold reported receiving personal fees from Sun Pharma, grants from Galderma, personal fees from Galderma, personal fees from Almirall, and grants from Ortho outside the submitted work. Dr. Herane has done research or been a speaker for Galderma, ISDIN, Vichy, La Roche Posay, and Abbott. Dr. Kang has served as a consultant or an advisory board member for Allergan, CeraVe, Galderma, and Unilever. Dr. Kircik has served either as an investigator, consultant, advisory board member, or speaker for Abbott, AbbVie, Ablynx, Aclaris, Amcambis, Allergan, Almirall, Amgen, Anacor Pharma, Anaptys, Arcutis, Arena, Assos Pharma, Astellas Pharma, Asubio, Bausch Health, Berlex Laboratories, Biogen-Idec, Biolife, Biopelle, Bristol Myers Squibb, Boehringer Ingelheim, Breckinridge Pharma, Cassiopea, Centocor, Cellceutix, Cipher, Coherus, Colbar, Combinatrix, Connectics Corporation, Coria, Dermavant, Dermira, Dermik Laboratories, Dow Pharmaceutical Sciences, Dr. Reddy’s Lab, Dusa, Embil Pharma, Eli Lilly, EOS, Exeltis, Ferndale Laboratories, Foamix, Ferrer, Galderma, Genentech, GlaxoSmithKline, Glenmark, Health Point, Idera, Incyte, Intendis, Innocutis, Innovail, Isdin, Johnson & Johnson, Kyowakirin, Laboratory Skin Care, Leo, L’Oréal, 3M, Maruho, Medical International Technologies, Merck, Medicis Pharma, Merz, Nano Bio, Novartis AG, Noven Pharma, Nucryst Pharma, Obagi, Onset, OrthoNeutrogena, PediaPharma, Pfizer, Promius, PuraCap, PharmaDerm, QLT, Quinnova, Quatrix, Regeneron, Sanofi, Serono, SkinMedica, Stiefel Laboratories, Sun Pharma, Taro, TolerRx, Triax, UCB, Valeant Pharma, Warner-Chilcott, XenoPort, and ZAGE; and Dr Kircik reported receiving personal fees from Sun Pharma during the conduct of the study. Dr. Mann has served as an investigator for Amgen, Celgene, and Target PharmaSolutions. Dr Oon reported receiving speaker fees and advisory board membership and researcher from Galderma, Janssen, and Novartis; she has also been a clinical investigator for Pfizer, as well as a speaker and advisory board member for AbbVie, Eli Lilly, and Leo Pharma. Dr. See has served either as an investigator, consultant, advisory board member, or speaker for Allergan, Galderma, La Roche Posay, Mayne Pharma, Next Science, and Viatris. Dr. Webster has received support from Galderma, Accure, and Hovione. Dr. Zip has served as an advisor and/or speaker for Amgen, Bausch Health, Loreal, Sun pharma, UCB, Leo Pharma, AbbVie, Galderma, Sanofi Genzyme, Janssen, Calgene, and Lilly. Dr. Zaenglein has served as an advisor for Cassiopea, Dermata, Sol-Gel, Verrica and has received research grants from AbbVie, Dermavant, Galderma and Incyte. She is co-editor of Pediatric Dermatology. Dr. Tan is an advisor, consultant, investigator, and/or speaker for: Allergan, Bausch, Boots Walgreens, Botanix, Cipher, Cutera, Dermavant, Galderma, Leo, L’Oréal, Novartis, Pfizer, and Sun Pharma. Dr Tapper has received research support from Bausch, Gilead, and Novo Nordisk, and has previously consulted for Allergan, Novartis, Novo Nordisk, Axcella, Kaleido, Mallinckrodt, Takeda, and Bausch outside the submitted work. Dr. Thiboutot reported serving as a consultant for Galderma and Novartis. Dr Mostaghimi reported receiving grants and personal fees from Pfizer, personal fees from Eli Lilly, personal fees and licensing from Concert, personal fees from Bioniz, holds equity and advisory board membership from Hims & Hers and Figure 1, personal fees from Digital Diagnostics, and personal fees from AbbVie outside the submitted work. No other disclosures were reported.
Disclaimer: John Barbieri, MD, MBA, and Arash Mostaghimi, MD, MPA, MPH, are Associate Editors of JAMA Dermatology, and Dr Barbieri is also Evidence-based Practice Editor, but they were not involved in any of the decisions regarding review of the manuscript or its acceptance.
2.Leyden
JJ , Del Rosso
JQ , Baum
EW . The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.
J Clin Aesthet Dermatol. 2014;7(2)(suppl):S3-S21.
PubMedGoogle Scholar 3.Singer
S , Tkachenko
E , Sharma
P , Barbieri
JS , Mostaghimi
A . Psychiatric adverse events in patients taking isotretinoin as reported in a Food and Drug Administration database from 1997 to 2017.
JAMA Dermatol. 2019;155(10):1162-1166. doi:
10.1001/jamadermatol.2019.1416PubMedGoogle ScholarCrossref 13.Barbieri
JS , Shin
DB , Wang
S , Margolis
DJ , Takeshita
J . The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time.
J Am Acad Dermatol. 2020;82(1):72-79. doi:
10.1016/j.jaad.2019.06.025PubMedGoogle ScholarCrossref 14.Hasson
F , Keeney
S , McKenna
H . Research guidelines for the Delphi survey technique.
J Adv Nurs. 2000;32(4):1008-1015.
PubMedGoogle Scholar 15.Engelman
D , Fuller
LC , Steer
AC ; International Alliance for the Control of Scabies Delphi panel. Consensus criteria for the diagnosis of scabies: a Delphi study of international experts.
PLoS Negl Trop Dis. 2018;12(5):e0006549. doi:
10.1371/journal.pntd.0006549PubMedGoogle ScholarCrossref 17.Ring
J , Alomar
A , Bieber
T ,
et al; European Dermatology Forum (EDF); European Academy of Dermatology and Venereology (EADV); European Federation of Allergy (EFA); European Task Force on Atopic Dermatitis (ETFAD); European Society of Pediatric Dermatology (ESPD); Global Allergy and Asthma European Network (GA2LEN). Guidelines for treatment of atopic eczema (atopic dermatitis) part I.
J Eur Acad Dermatol Venereol. 2012;26(8):1045-1060. doi:
10.1111/j.1468-3083.2012.04635.xPubMedGoogle ScholarCrossref 18.Harris
PA , Taylor
R , Thielke
R , Payne
J , Gonzalez
N , Conde
JG . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
J Biomed Inform. 2009;42(2):377-381. doi:
10.1016/j.jbi.2008.08.010PubMedGoogle ScholarCrossref 26.Webster
GF , Webster
TG , Grimes
LR . Laboratory tests in patients treated with isotretinoin: occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality.
Dermatol Online J. 2017;23(5):13030/qt7rv7j80p. doi:
10.5070/D3235034929PubMedGoogle ScholarCrossref 27.Galarraga
B , Sinclair
D , Fahie-Wilson
MN , McCrae
FC , Hull
RG , Ledingham
JM . A rare but important cause for a raised serum creatine kinase concentration: two case reports and a literature review.
Rheumatology (Oxford). 2003;42(1):186-188. doi:
10.1093/rheumatology/keg039PubMedGoogle ScholarCrossref 31.Opel
D , Kramer
ON , Chevalier
M , Bigby
M , Albrecht
J . Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis.
Br J Dermatol. 2017;177(4):960-966. doi:
10.1111/bjd.15207PubMedGoogle ScholarCrossref